Scholastic's YouTube surge, 85M views, up 200%, signals a strategic shift, turning digital platforms into engines for ...
Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.
Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), ...
71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a ...
Shares of Pearson PLC PSON rose 2.47% to £9.77 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 1.61% to 10,127.96. Pearson ...
High rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies.- Completely clear skin achieved at Week 52 in nearly 60% of adolescents treated with ...
April brings cool concert acts to the Pittsburgh region. From Kenny Wayne Shepherd to The Temptations; and a Flock of Seagulls to Bush and BBMak, there’s a show for all musical tastes. Here’s the ...
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies ...
Zacks Investment Research on MSN
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why
Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results